Clinical Studies:


Summarized by Lediana Goduni, MD

Citations: Campochiaro PA, Brown DM, Awh CC, et al. Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study. Ophthalmology 2011;118:2041–2049

Key Points

  • CRUISE is a prospective study that evaluated the visual and anatomic outcomes of patients with macular edema secondary to central retinal vein occlusion (CRVO) who received either prompt monthly ranibizumab (0.3mg or 0.5mg) injections or sham injections for six months followed by a six month observation period during which all patients were eligible for monthly ranibizumab injections based on certain criteria.
  • The treatment groups achieved significant gains in vision by six months and these were maintained at one year, with a mean BCVA letter score gain of 13.9 in both treatment groups.
  • In the sham group, the mean gain in BCVA letter score was only 0.8 at six months. After the initiation of as needed monthly ranibizumab injections, there was an increase in BCVA letter score (mean 7.3), but it was not as substantial as the gains in the treatment groups.
  • All groups had significant and relatively similar anatomic improvement as measured by a decrease in central foveal thickness (CFT) at month 12.
  • Objective

    To assess the efficacy and safety of intravitreal ranibizumab injections (0.3 mg or 0.5 mg) in the treatment of macular edema secondary to CRVO.


    Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial.



After the initial 6 month study of strict monthly injections, all patients (study and control) were eligible for intravitreal ranibizumab injections if best corrected visual acuity (BCVA) was 20/40 or less or the mean CFT was 250µm or greater on OCT. Patients were examined on a monthly basis. The study patients who had received ranibizumab injections in the first half of the study would receive their previously established dose while patients previously in the sham group would receive 0.5mg of ranibizumab when eligible.


Study population

Follow-up time

Visual acuity end-points


Anatomic outcomes